Doripenem vs meropenem against Pseudomonas and Acinetobacter.
Indian J Med Microbiol
;
2012 Jul-Sept; 30(3): 350-351
Article
in English
| IMSEAR
| ID: sea-143983
ABSTRACT
Recently, doripenem has been approved for the treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP). The E-test was performed to determine the MICs of doripenem and meropenem in 203 endotracheal aspirate isolates that consisted of 140 Acinetobacter calcoaceticus-Acinetobacter baumannii complexes and 63 Pseudomonas aeruginosa. Doripenem showed minimum concentration necessary for inhibition of 50% (MIC 50 ) of P. aeruginosa isolates at 0.38 mg/L which is several times (84.2 times) lower than the corresponding MIC 50 value of >32 mg/L for meropenem. The MIC 50 and MIC 90 were similar for both the drugs against A. baumannii. Thus, P. aeruginosa was consistently more susceptible than the A. baumannii.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Pseudomonas aeruginosa
/
Pseudomonas Infections
/
Acinetobacter Infections
/
Humans
/
Microbial Sensitivity Tests
/
Carbapenems
/
Thienamycins
/
Acinetobacter calcoaceticus
/
Acinetobacter baumannii
/
Pneumonia, Ventilator-Associated
Language:
English
Journal:
Indian J Med Microbiol
Journal subject:
Microbiology
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS